Jay Shepard Sells 14,446 Shares of Versartis Inc (VSAR) Stock
Versartis Inc (NASDAQ:VSAR) insider Jay Shepard sold 14,446 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $1.80, for a total value of $26,002.80. Following the completion of the transaction, the insider now directly owns 602,298 shares in the company, valued at approximately $1,084,136.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Versartis Inc (VSAR) opened at $1.80 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52. The company has a market capitalization of $60.88, a PE ratio of -0.46 and a beta of 2.11. Versartis Inc has a 1 year low of $1.60 and a 1 year high of $24.00.
VSAR has been the topic of a number of recent research reports. Cantor Fitzgerald set a $14.00 target price on Versartis and gave the company a “buy” rating in a report on Friday, October 27th. Zacks Investment Research downgraded Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $5.63.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.